DJIA 17,778.15 421.28 2.43%
NASDAQ 4,748.40 104.08 2.24%
S&P 500 2,061.23 48.34 2.40%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.90 0.86 (2.39%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $36.90 2.39%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $36.71
Previous Close $36.04
Daily Range $36.57 - $37.06
52-Week Range $33.16 - $38.71
Market Cap $207.4B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 1,227,277
Average Daily Volume 944,157
Current FY EPS $1.95

Sector

Healthcare

Industry

Pharmaceuticals

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary Rss Feed

3 Beaten Down Stocks Ready to Bounce Back

Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.

This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year

A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.

This is Incredibly Good News for Breast Cancer Survivors

A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.

Why Inovio Pharmaceuticals Inc. Stock Plunged 15% in November

Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.

This High-Yield Dividend Stock Screams Danger

This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.

Why Shareholders of Organovo Holdings Inc Have Been Waiting For This Day

This 3D bioprinting company finally has a product on the market.

Why Novartis and Regeneron Care About This Tiny Biotech Stock

Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.

Why Exelixis, Inc. Stock Pushed 11% Higher in October

Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.90 (2.39%)
Current stock: RHHBY
JNJ $106.81 (2.63%)
Current stock: JNJ
NVS $94.57 (2.47%)
Current stock: NVS
GSK $43.29 (2.97%)
Current stock: GSK